28 "Pancreas" clinical trials found.
-
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1 BRCA2 or PALB2 Mutation
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that ...
Phase
Match Level: Exact
-
PHASE II/III SECOND-LINE NABPLAGEM VS. NAB-PACLITAXEL/GEMCITABINE IN BRCA1/2 OR PALB2 MUTANT METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PLATINUM)
This is a phase II/III study testing whether the study medicines, Nab-paclitaxel plus cisplatin and gemcitabine, work better than the standard chemotherapy medicine Nab-paclitaxel plus ...
Phase
Match Level: Exact
-
Phase I Pilot study of Endoscopic Ultrasound guided RFA in advanced pancreatic cancer
This study is testing how using a procedure called endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) together with chemotherapy before surgery (Neoadjuvant) can be safe and effective ...
Phase
Match Level: Exact
-
A Study to Assess the Safety of Intratumoral Diffusing Alpha Radiation Emitters with Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
This is a one-arm study testing whether the new treatment with Alpha DaRT (a medical device fitted inside the tumor that emits radiation), together with ...
Phase N/A Match Level: Exact
-
A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
The purpose of this study is to test the safety of a study drug called TJ033721. The study will test different dose levels to find ...
Phase
Match Level: Exact
-
A PHASE 1 FIRST IN HUMAN DOSE ESCALATION AND EXPANSION MULTICENTER STUDY OF XMT- 2056 IN PARTICIPANTS WITH ADVANCED/RECURRENT SOLID TUMORS THAT EXPRESS HER2
The proposed first-in-human study of XMT-2056 will be a Phase 1, open-label study of XMT-2056 in previously treated patients with advanced/recurrent solid tumors expressing HER2. ...
Phase
Match Level: Exact
-
A Phase 1/2 Open-Label Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination with an anti-PD-1 Antibody in Patients with STK11-Mutated Advanced Solid Tumors
This is a first-in-human Phase 1/2, open-label, multicenter, dose-escalation and -expansion study designed to determine the MTD of TNG260 as single agent and in combination ...
Phase
Match Level: Exact
-
A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with VS-6766 and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma ...
Phase
Match Level: Exact
-
Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
Phase
Match Level: Exact
-
A Phase 1 Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma
This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with ...
Phase
Match Level: Exact
